Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a strong sell rating in a research report sent to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings cut Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, June 29th. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Oppenheimer reissued an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Wedbush lifted their price target on Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 26th. Finally, Citigroup upped their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Nine research analysts have rated the stock with a Buy rating, ten have given a Hold rating and seven have given a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus price target of $24.91.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $20.21 on Tuesday. The company has a 50-day simple moving average of $17.80 and a 200-day simple moving average of $19.29. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. The company has a market cap of $2.13 billion, a PE ratio of -21.05, a price-to-earnings-growth ratio of 0.21 and a beta of 0.21. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $2.18. The business had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.42) earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth about $25,000. Ancora Advisors LLC increased its position in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares in the last quarter. Allworth Financial LP increased its position in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,256 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.